Ms Gilbert joined the Arcutis board in May 2020. She brings more than 20 years of experience in legal, corporate and business development, compliance, and government affairs. Ms Gilbert is currently chief legal officer and chief operating officer of Tubulis, where she oversees legal and administrative functions and helps shape corporate strategy and U.S. expansion at a pivotal stage of clinical and corporate growth.
Most recently, Ms Gilbert served as chief legal officer of Cargo Therapeutics, where she played a key leadership role in the company’s initial public offering and subsequent sale. Prior to Cargo, she served as chief legal officer at NeoGenomics, Inc., a premier cancer diagnostics, pharma services, and informatics company. Earlier, she was the first employee and chief operating officer at Adagio Therapeutics (now Invivyd, Inc.). She helped scale the company from launch through IPO and supported its transition from early R&D to late-stage clinical development.
Previously, Ms Gilbert spent 12 years in roles of increasing scope at Ironwood Pharmaceuticals, Inc., including senior vice president of corporate development and chief dministrative officer, where she oversaw corporate and business development, legal, compliance, and government affairs, and as senior vice president, chief legal officer, and corporate secretary. Before Ironwood, she was vice president, deputy general counsel at Cubist Pharmaceuticals, Inc., and earlier served as corporate counsel at Genzyme Corp., prior to its acquisition by Sanofi. She began her career at Skadden, Arps, Slate, Meagher & Flom LLP, specializing in mergers and acquisitions and securities law.
Ms Gilbert currently serves on the boards of directors of CytomX TherapeuticsandVaxcyte, Inc. (in addition to Arcutis). Previous board roles included Dermira, Inc., prior to its acquisition by Eli Lilly and Company, and Achaogen, Inc.
Ms Gilbert holds a BA from Tufts University and a JD from Northwestern University School of Law.
What is Halley E. Gilbert's net worth?
The estimated net worth of Halley E. Gilbert is at least $589.58 thousand as of November 20th, 2025. Gilbert owns 22,123 shares of Arcutis Biotherapeutics stock worth more than $589,578 as of January 22nd. This net worth approximation does not reflect any other investments that Gilbert may own. Learn More about Halley E. Gilbert's net worth.
How do I contact Halley E. Gilbert?
Has Halley E. Gilbert been buying or selling shares of Arcutis Biotherapeutics?
Halley E. Gilbert has not been actively trading shares of Arcutis Biotherapeutics within the last three months. Most recently, Halley E. Gilbert sold 16,532 shares of the business's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $27.55, for a transaction totalling $455,456.60. Following the completion of the sale, the director now directly owns 22,123 shares of the company's stock, valued at $609,488.65. Learn More on Halley E. Gilbert's trading history.
Who are Arcutis Biotherapeutics' active insiders?
Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Halley Gilbert (Director), Patrick Heron (Director), Neha Krishnamohan (Director), Sue-Jean Lin (Director), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Latha Vairavan (CFO), Todd Watanabe (Insider), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?
During the last year, Arcutis Biotherapeutics insiders bought shares 4 times. They purchased a total of 7,434 shares worth more than $99,276.66. During the last year, insiders at the sold shares 51 times. They sold a total of 551,438 shares worth more than $11,983,811.39. The most recent insider tranaction occured on January, 5th when insider Patrick Burnett sold 2,490 shares worth more than $72,160.20. Insiders at Arcutis Biotherapeutics own 9.4% of the company.
Learn More about insider trades at Arcutis Biotherapeutics. Information on this page was last updated on 1/5/2026.
